Orchestra BioMed Holdings (OBIO) Return on Capital Employed (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of Return on Capital Employed data on file, last reported at 58.43% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 7356.0% year-over-year to 58.43% in Q1 2026; TTM through Mar 2026 was 58.43%, a 7356.0% increase from a year earlier, with the FY2025 full-year figure at 65.76%, up 2678.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 58.43%, down from 55.65% in the prior quarter.
• Over the last five years, Return on Capital Employed for OBIO reached as high as 3.35% in Q1 2022 and fell as low as 210.37% in Q2 2025.
• Historically, Return on Capital Employed has averaged 72.55% across 5 years, with a median of 55.65% in 2025.
• Across the five-year window, Return on Capital Employed slumped 11785 bps in 2025 and jumped 7356 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 51.39% in 2022, then slipped by 6 bps to 54.46% in 2023, then tumbled by 98 bps to 108.0% in 2024, then soared by 48 bps to 55.65% in 2025, then decreased by 5 bps to 58.43% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 58.43% in Q1 2026, 55.65% in Q4 2025, and 141.53% in Q3 2025.